Type I cells are characterized by slower growth, cancer stem-like properties, and a high level of MyD88 [24], which contributes to ovarian cancer progression by inducing epithelial ovarian cancer cell proliferation [28], survival [15–20], and metastasis [29], as well as tumor angiogenesis [30] and paclitaxel chemoresistance [24]. Here, MYD88 is linked to ovarian cancer.